Comments on StockTalk's statements:
All peptide devices are "self assembling". None rely on body chemistry or temperature for formation. There are other devices that use other technologies to form 'in situ'.
StockTalk says AC5 is unique, and then later states it has a lot of imitators. Which is it? FYI, PuraStat (using MIT-licensed 'self assembling peptide technology) is in the GI marketplace and is apparently the inspiration for ARTH comments about GI marketplace potential. (Cook Medical & others also have devices for this application.)
While most wound dressings don't use peptide technology, AC5 clinical performance and function is not so different from the established competition (except that it does not manage wound exudate). No wound dressing is great for all clinical situations, but a large number could be used effectively to close the wounds in the anecdotal reports provided by ARTH. There are always failures in difficult cases, and clinicians often have to try several until one works in a particular case. Many years after development, no prospective clinical studies using an acceptable control device for comparison exist. One needs data to be accepted onto a hopsital formulary these days, no poetic interpretations of bench data or anecdotal clinical reports are sufficient for this task. AC5 seems to be an answer to clinical problems that already have satisfactory solutions. This seems to be the reason why there have been no strategic partnerships.
Thrombin is a drug used to trigger hemostasis on surgical wounds; it is not a wound dressing. Comparison to AC5 is a red herring. Based on the information about AC5, it is extremely unlikely that it would be a successful absorbable hemostat for use in surgery. (This fact must hurt, as it goes to the heart of a fiction.)
The comments about supply chain are an unusual interpretation of the facts. AC5 could have been launched with the initial supply chain had there been demand for it in the market place.
ST's notes correctly that ARTH is a medical device company. Pre-revenue biotech companies can raise capital in today's environment, especially when addrssing oncologic or chronic disease conditions. Pre-revenue 'me-too' Medical device companies have a much more diffiocult time doing so, espcially when there has been no progress for a long time and the marketplace is crowded.
Question: Does ARTHG have a marketing & sales team on board? No evidence about this from public statements. How does one launch a device without a marketing & sales team? ARTH beeds someone to find a use for AC5 in which it excells and other devices do not. Can't think of any at the moment, but a marketing person might.
News 
Market Data 
Discover 
